US FDA Seeks Withdrawal Of Injectable Bacitracin Despite Extensive Off-Label Use
Executive Summary
Injectable bacitracin, often used as a surgical irrigant, carries serious risks of nephrotoxicity and anaphylaxis; product is no longer prescribed for its lone approved indication in pediatric pneumonia. FDA’s decision aligns with advisory committee recommendations in 1984 and 2019.